EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Treatment success rate and time to culture conversion under a prospective BPaL cohort study

E. Burhan, J. Sugiharto, M. Soemarno, A. Juan, Y. Runtu, A. Yuvensia, R. Ramadhani, J. Sabono, A. Lailiyah, F. Fenni, M. Farikha, T. Pakasi, I. Pambudi, M. Mbenga, I. Koppelaar, V. Mirtskhulava, F. Wares, D. Jerene, J.K. Jung, J.S. Lee, S. Foraida, S. Juneja, M. Diachenko, A. Gebhard

IJTLD Open · 2025-05 · 2 (5) · 284-290

DOI: 10.5588/ijtldopen.24.0524 ↗
AbstractBibliografische Angaben

Abstract

SUMMARY BACKGROUND In July 2022, Indonesia implemented the 6-month BPaL (bedaquiline, pretomanid, linezolid) regimen under operational research (OR) for selected drug-resistant tuberculosis patients. The study aimed to assess treatment success rate (TSR) and time to sputum culture conversion (TSCC). METHODS A prospective cohort study in fifteen sites between July 2022 and March 2023 enrolled patients with rifampicin-resistant/multidrug-resistant TB with additional fluoroquinolone resistance or intolerance/failures of previous second-line TB treatment. TSR was descriptively analysed, and Kaplan-Meier and Cox proportional-hazards analyses were used to evaluate TSCC. RESULTS A total of 87 patients were enrolled, 3 were withdrawn, and 84 completed treatment and had outcomes; 82 (97.6%) patients had successful treatment, 1 (1.2%) died, and 1 (1.2%) had failure. Overall, 61 (72.6%) patients had positive cultures at baseline, and favourable outcomes were included in the TSCC analysis; all 61 (100%) converted within the first 3 months (median 32 days of treatment, IQR 30.0–56.0). None of the six variables were statistically associated with conversion time. CONCLUSION The Indonesian BPaL OR showed a highly promising TSR of 97.6%, with 100% sputum conversion within 3 months. The lack of observed statistical differences in the TSCC across variables shows that the BPaL treatment will be equally effective in all patient groups.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →